Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
Authors
Keywords
-
Journal
Therapeutic Advances in Chronic Disease
Volume 7, Issue 4, Pages 198-207
Publisher
SAGE Publications
Online
2016-06-11
DOI
10.1177/2040622316653307
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States
- (2016) Josephine Mauskopf et al. JOURNAL OF MEDICAL ECONOMICS
- Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS
- (2015) Benedetta Parodi et al. ACTA NEUROPATHOLOGICA
- Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system
- (2015) Bernd C. Kieseier et al. ACTA NEUROPATHOLOGICA
- Cell type-specific Nrf2 expression in multiple sclerosis lesions
- (2015) Simon Licht-Mayer et al. ACTA NEUROPATHOLOGICA
- Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
- (2015) John O’Gorman et al. CLINICAL THERAPEUTICS
- Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies
- (2015) Gavin Giovannoni et al. CLINICAL THERAPEUTICS
- Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
- (2015) L. Kappos et al. EUROPEAN JOURNAL OF NEUROLOGY
- Dimethyl fumarate attenuates cerebral edema formation by protecting the blood–brain barrier integrity
- (2015) Reiner Kunze et al. EXPERIMENTAL NEUROLOGY
- Dimethyl fumarate suppresses Theiler’s murine encephalomyelitis virus-induced demyelinating disease by modifying the Nrf2-Keap1 pathway
- (2015) Kunitoshi Kobayashi et al. INTERNATIONAL IMMUNOLOGY
- Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells
- (2015) Axel Haarmann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner
- (2015) Geoffrey O. Gillard et al. JOURNAL OF NEUROIMMUNOLOGY
- Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage
- (2015) Loretta O. Iniaghe et al. NEUROBIOLOGY OF DISEASE
- PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate
- (2015) Dennis J. Nieuwkamp et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
- (2015) Thorsten Rosenkranz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection
- (2015) Kalliopi Pitarokoili et al. PLoS One
- Effects of dimethyl fumarate on lymphocyte subsets
- (2015) Regina Berkovich et al. Multiple Sclerosis and Related Disorders
- Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro
- (2015) Melanie S. Brennan et al. PLoS One
- Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
- (2014) Mariko Kita et al. CLINICAL THERAPEUTICS
- Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation
- (2014) Christiane Reick et al. EXPERIMENTAL NEUROLOGY
- Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
- (2014) Hui Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
- (2014) Douglas L. Arnold et al. JOURNAL OF NEUROLOGY
- Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
- (2014) Douglas L. Arnold et al. JOURNAL OF NEUROLOGY
- Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
- (2014) Ralf Gold et al. Multiple Sclerosis Journal
- Dimethyl fumarate associated lymphopenia in clinical practice
- (2014) Erin E Longbrake et al. Multiple Sclerosis Journal
- Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel
- (2014) J. Theodore Phillips et al. Multiple Sclerosis and Related Disorders
- Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study
- (2014) Katrin Strassburger-Krogias et al. Therapeutic Advances in Neurological Disorders
- Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers
- (2013) Sarah I. Sheikh et al. CLINICAL THERAPEUTICS
- Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison
- (2013) Michael Hutchinson et al. CURRENT MEDICAL RESEARCH AND OPINION
- Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study
- (2013) Michael Hutchinson et al. JOURNAL OF NEUROLOGY
- Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study
- (2013) Amit Bar-Or et al. JOURNAL OF NEUROLOGY
- Effects of fumaric acid esters on blood–brain barrier tight junction proteins
- (2013) Karelle Bénardais et al. NEUROSCIENCE LETTERS
- Fumarate Is Cardioprotective via Activation of the Nrf2 Antioxidant Pathway
- (2012) Houman Ashrafian et al. Cell Metabolism
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
- (2011) Kamran Ghoreschi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
- (2011) Gisa Ellrichmann et al. PLoS One
- The Nrf2-ARE Pathway
- (2010) Jeffrey A. Johnson et al. Annals of the New York Academy of Sciences
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis
- (2010) D. G. MacManus et al. JOURNAL OF NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search